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vivors (‘survivorship issues’), and coping with disease-
related symptoms and the side effects of treatment. Fur-
ther important issues on the agenda were the use of 
standardized instruments for the assessment of individ-
ual treatment success (‘patient-reported outcome meas-
ures’) and the evaluation of the benefit of novel drugs 
(e.g. the European Society for Medical Oncology (ESMO) 
Magnitude of Clinical Benefit Scale). Diagnosis and treat-
ment of inoperable locally advanced breast cancer had 
already been discussed 2 years earlier at the ABC2 Con-
sensus and were not dealt with in the framework of this 
year’s ABC3 Consensus. With regard to country-specific 
peculiarities, which unavoidably found their way into the 
ABC Consensus, a working group of German breast can-
cer experts commented on the voting results of the ABC 
panelists. As for the past consensus, the group specially 
considered the German guidelines for the diagnosis and 
treatment of breast cancer (AGO (Gyneco-Oncology 
Working Group), S3, DGHO (German Society of Hema-
tology and Medical Oncology)) in order to adapt the 
ABC3 consensus for everyday therapy in Germany.
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Summary
The Advanced Breast Cancer Third International Consen-
sus Conference on the diagnosis and treatment of ad-
vanced breast cancer took place in Lisbon, Portugal, on 
November 5–7, 2015. This year’s conference (ABC3) was 
focused on the treatment of metastatic breast cancer 
(stage IV), as it was 4 years ago at the first consensus 
meeting (ABC1). A matter of particular interest was the 
patients’ perspective. Thus, patient-relevant issues were 
addressed by the consensus discussions, such as those 
on treatment goals, quality of life, care of long-term sur-
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Introduction
The organizer of the Advanced and Metastatic Breast Cancer 
Consensus (ABC) Conference is the European School of Oncology 
(ESO). The recommendations of this year’s third ABC Consensus 
(ABC3) will be published, as usual, in the journal The Breast. The 
consensus is held in coordination with various international socie-
ties: the European Society for Medical Oncology (ESMO), the Eu-
ropean Society of Breast Cancer Specialists (EUSOMA), the Feder-
ación Latinoamericana de Mastología (Latin-American Federation 
of Mastology (FLAM)) and the Senologic International Society 
(SIS). The ABC3 Consensus is also supported by the Breast Cancer 
Research Foundation (BCRF) and the Susan G. Komen Breast 
Cancer Foundation.
The goal of the ABC Consensus is the international harmoniza-
tion and standardization of treatment for patients with locally ad-
vanced and/or metastatic breast cancer. The main topic of this 
year’s ABC3 Consensus, just like 4 years ago during the first ABC1 
Consensus, was metastatic breast cancer (stage IV). This year, a 
particular focus was on taking the patient’s perspective into ac-
count. Patient-relevant issues were addressed by the consensus dis-
cussions, such as those on the aims of treatment, quality of life, 
care of long-term survivors (‘survivorship issues’), and coping with 
disease-related symptoms and the side effects of treatment. Further 
important discussion topics were the use of standardized instru-
ments for the assessment of individual treatment success (‘patient-
reported outcome measures’) and the evaluation of the benefit of 
novel drugs (e.g. the ESMO Magnitude of Clinical Benefit Scale 
(ESMO-MCBS)). The diagnosis and therapy of inoperable locally 
advanced breast cancer (stage IIIB) were discussed in the frame-
work of the ABC2 Consensus conference, held in November 2013 
in Lisbon, Portugal [1].
The ABC3 panel included 45 experts from 23 countries 
(table 1), among them 2 representatives from Germany (Prof. Dr. 
med. Nadia Harbeck and Prof. Dr. med. Christoph Thomssen) as 
well as 6 patient representatives and/or nursing staff. The goal is to 
create a valid foundation on which an individual, evidence-based 
therapeutic decision can be made. The statements submitted to a 
vote were assessed by the panelists with ‘yes’ (approval), ‘no’ (rejec-
tion), or ‘abstention’. The voting results are based on the opinions 
of experts from different specialties who come from countries with 
different healthcare systems and resources. It seems therefore rea-
sonable to discuss the voting results from a German perspective in 
order to substantiate them for everyday clinical practice in Ger-
many. As for the past consensus, the group specially considered the 
German guidelines for the diagnosis and treatment of breast cancer 
(AGO (Arbeitsgemeinschaft für gynäkologische Onkologie (Gy-
neco-Oncology Working Group)), S3, DGHO (Deutsche Gesells-
chaft für Hämatologie und Medizinische Onkologie (German Soci-
ety of Hematology and Medical Oncology)) [2–5] in order to adapt 
the ABC3 consensus for everyday therapy in Germany.
The statements discussed in the present publication of the con-
sensus conference make up the current state of debate as of the Lis-
bon symposium on November 7, 2015. The final recommendations 
of the ABC3 Consensus may include additional updates. The au-
thors refer to the official publication of the ABC3 Consensus State-
ment (expected: Cardoso F et al., Breast 2016).
General Statements Regarding Advanced  
Breast Cancer
Clinical Evaluation of the Benefit of Drugs by ESMO and ASCO
Aimed at supporting the oncologically active physicians with 
their assessment of the efficacy of cancer drugs, the ESMO and the 
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American Society of Clinical Oncology (ASCO) in the USA each 
developed new instruments: the ESMO-MCBS [6] and the ‘ASCO 
Value Framework’ [7], respectively. The aim is to create a stand-
ardized and balanced, objective assessment of new therapies at an 
international level. Based on criteria such as overall survival (OS) 
or progression-free survival (PFS) prolongation, toxicity, and/or 
quality of life, new drugs are classified as having high, medium, or 
only little clinical benefit. A large majority (87.5%) of the ABC3 
panelists welcome the new scales, particularly in order to make 
sure that drugs with a good benefit assessment be used and funded 
in countries with limited resources (level of evidence (LoE): expert 
opinion).
The German group of experts welcomes these scales on the 
grounds of possibly achieving an internationally standardized eval-
uation and treatment. In particular, the ESMO-MCBS, which takes 
into account the PFS and OS as well as the quality of life and toxic-
ity, allows a target-oriented approach in order to expand the dis-
cussion regarding the importance of the study endpoints ‘OS’ ver-
sus ‘PFS’. On the other hand, the ASCO scale very strongly empha-
sizes the cost issue, which is a crucial aspect in the American health 
system. The German experts specifically point out that, in Ger-
many, neither the ESMO nor the ASCO scale has an influence on 
the final therapeutic decision. The physician in consultation with 
the patient decides on this individually.
The Importance of Telemedicine
Almost every ABC3 panelist (92.8%) considers telemedicine to 
be an important treatment-supporting approach for patients living 
in rural or sparsely populated areas located far from oncological 
centers. Prerequisite is the secure use of proper information and 
communication technologies (LoE: expert opinion). The German 
group of experts agrees with this statement and adds that the cost 
reimbursement for this important cooperation has not yet been 
regulated and, in this regard, a solution still has to be found.
‘Patient-Reported Outcome Measures’
A clear majority of the ABC3 panelists (87.1%) advocate the rou-
tine (on a day-to-day basis) clinical use of validated instruments 
that aim at estimating the side effects of oncological treatments and 
disease-related complaints. These patient-reported outcome meas-
ures (PROMs) should be easy to use and clinically manageable on a 
day-to-day basis. This also includes an uncomplicated application, 
e.g. by means of cell phones. The systematic monitoring thus ena-
bled facilitates communication between the patient and the treat-
ment team since the undesired treatment side effects can be more 
reliably documented and more rapidly communicated. In addition, 
earlier intervention by supportive measures is possible, which 
means a better quality of life for the patients (LoE: IC).
From the German perspective, the routine use of these instru-
ments is principally to be welcomed; however, it seems to be a 
rather unrealistic vision, considering the scarce financial resources 
of breast centers and of practicing doctors. For the routine use of 
PROMs, appropriate additional resources, e.g., for documentation 
and processing, must be secured.
Treatment of Long-Term Survivors (‘Survivorship Issues’)
Due to the improved therapeutic options, the survival period of 
patients with advanced and metastatic breast cancer is growing 
longer and longer. This poses new challenges for the day-to-day 
clinical practice. 95% of the ABC3 panelists voted for a treatment 
strategy that must be regularly adapted to the disease status of the 
patient. Herein, therapeutic effects also play a role, such as the pa-
tient’s quality of life, her expectations from treatment, and her cur-
rent life plans. When planning the therapy, special attention must 
be paid to the nursing needs of the patient, the support of her fam-
ily, and her professional and social integration (LoE: expert 
opinion).
The German experts point out that the gain in terms of survival 
of patients with metastatic disease varies greatly according to sub-
type. Nevertheless, the demands of the ABC3 panelists are impor-
tant. In Germany, there are several ‘lighthouse projects’ such as, 
e.g., the ‘German Foundation for Young Adults with Cancer’ [8], 
but a comprehensive provision of care or an adequate lobbying for 
these patients is still missing. The German experts add that a scien-
tific evaluation in the frame of healthcare research is urgently 
required.
All ABC3 panelists (100%) and the German experts agree that 
the desire of the patient to continue working during therapy must 
be taken into account during therapy planning, but also that an ap-
propriate flexibility of the workplace must be available. In spite of 
the professional activity of the patient, the continuity of treatment 
must be guaranteed (LoE: expert opinion). This should, in the ex-
perts’ opinion, not only be self-evident for the patients, but also 
society and the workplace must accept and implement this princi-
ple accordingly.
Patients with Stable Disease
More than 80% of the ABC3 panelists (82%) are of the opinion 
that, for patients in a stable stage of their metastatic disease 
(‘chronic condition’), oncoplastic breast reconstruction may be an 
option (LoE: expert opinion). The German group of experts con-
siders the option of oncoplastic breast reconstruction in patients 
with metastatic disease to be feasible only in a long-term stable sit-
uation under systematic treatment. Breast reconstruction should 
be discussed only if the patient herself desires it. It should be con-
sidered only if the dynamics of the disease is low and a longer life 
expectancy is expected. In a purely palliative stage of the disease 
with an unstable response to treatment or extensive ‘high-risk’ 
metastatic spread, such an intervention does not make sense.
The ABC3 panelists disagreed regarding the question on 
whether patients with advanced disease who are stable for a long 
period should have regular breast imaging or whether breast imag-
ing is only warranted in case of a suspected local or regional pro-
gression. Just over half of the ABC3 panelists (52.5%) voted for and 
somewhat less than a half (47.5%) voted against regular breast im-
aging (LoE: expert opinion).
From the German perspective, it is self-evident that a patient 
with metastatic disease must undergo physical examination at regu-
lar time intervals. In the event of a suspected local or regional pro-
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gression, breast imaging is indicated if the result of the imaging di-
agnosis may have clinical consequences. For patients who are free of 
symptoms or who do not have a suspected finding, there is no indi-
cation – from the German perspective – for regular breast imaging.
Biopsy of a Metastatic Lesion
The ABC3 panelists (97.6%) and the German group of experts 
agree that a biopsy of an easily accessible metastatic lesion is impor-
tant not only for histological confirmation but also for verification 
of the primary tumor diagnosis. Biopsy of a metastatic lesion is par-
ticularly recommended at the first appearance of metastases (LoE: 
1B). The tumor biology and, in particular, the hormone receptor 
(HR) and human epidermal growth factor receptor 2 (HER2) status 
should be re-evaluated at least once in the metastatic stage, if this is 
clinically feasible (LoE: 1B). Depending on the localization of the 
metastasis (e.g. bone), technical difficulties during tissue examina-
tion should be discussed in advance with the pathologist.
The German experts add that discordant results warrant serial 
tissue collection and analysis during the course of the disease. 
Technically, in addition to a punch biopsy, a fine-needle aspiration 
for cytology (e.g., fluorescence in situ hybridization (FISH) in a cy-
tological sample) may also be considered. From the German per-
spective, the biopsy of a metastatic lesion is also useful in case of an 
unexpected lack of response.
Resection of the Primary Tumor
Resection of the primary tumor in primary metastatic patients 
does not usually prolong survival, with the potential exception of 
breast cancers with merely bone metastases (LoE: 1B). Notwith-
standing, breast tumor surgery can be considered in individually 
selected cases, in particular if an improved quality of life can 
thereby be expected (LoE: 2B). Just over 70% of the ABC3 panelists 
agreed on this. Prospective clinical trials are currently investigating 
this approach. Among others, the issues in question are as to which 
patients should primarily be considered for surgery and which 
point in time would be optimal.
The German group of experts points out that these decisions 
must be discussed individually with the patient, because no pro-
longed life expectancy has been proven to date. On the contrary, in 
the presence of visceral metastases, surgery can sometimes even 
have negative consequences. Therefore, surgery should only be 
considered upon request of a properly informed patient. In addi-
tion, such a patient should be stable for a long time under systemic 
treatment and should still have a reasonably long life expectancy 
and low disease dynamics. If the primary tumor is operated on, it 
must be removed with surrounding healthy tissue. The German ex-
perts point out that a clinically free axilla should not be treated sur-
gically in this situation. Resection of the primary tumor is con-
traindicated in patients with poor response to systemic therapy and 
‘high-risk’ metastases.
Chances of Long-Term Survival?
The German expert group agrees with the ABC3 panelists (90.6%) 
that a small percentage of patients in an advanced stage of the disease 
have a chance of long-term survival. Usually, these are patients with 
oligometastatic disease or with a low metastatic burden, who respond 
well to systemic treatment and achieve a complete clinical remission. 
This group of patients should receive multimodal treatment, includ-
ing local and regional therapeutic measures applied in a quasi-cura-
tive setting (LoE: expert opinion). For further validation of this ap-
proach, a prospective clinical trial is recommended.
HER2-Positive Metastatic Breast Cancer
It is not controversial that patients with HER2-positive ad-
vanced or metastatic breast cancer should be offered an anti-
HER2-targeted treatment as early as in the first-line therapy, if 
there are no contraindications (LoE: 1A).
ER+/HER2+ Metastatic Disease
Patients with HER2+ advanced breast cancer require anti-
HER2-targeted therapy, independent of their HR status. This ap-
plies also to the rare cases in which endocrine therapy is preferred 
over chemotherapy. The German group of experts and the ABC3 
panelists (72.0%) are in full agreement in this respect.
Up to now, no study has compared a first-line treatment with 
an endocrine agent plus an anti-HER2-targeted substance to chem-
otherapy plus an anti-HER2-targeted substance (LoE: 1A). The in-
direct comparison is in favor of chemotherapy: To date, no benefit 
in terms of survival could be documented for the combination of 
endocrine plus anti-HER2-targeted treatment, unlike for the first-
line treatment with chemotherapy plus anti-HER2-targeted sub-
stances [9].
From the German perspective, the application of endocrine 
therapy in the first-line situation should be very restrictive. The 
German experts point out that, except for clinical studies, the first-
line application of endocrine therapy in patients with HER2+ and 
estrogen receptor-positive (ER+) advanced breast cancer could be 
an option only if chemotherapy cannot be administered or is re-
fused by the patient [2]. In Germany, chemotherapy plus dual 
HER2 blockade is the standard first-line therapy for patients with 
HER2-positive metastatic breast cancer, irrespective of the HR sta-
tus. Currently, the DETECT V study (Chemo vs. Endo (CHEV-
ENDO)) is running in Germany, dealing with precisely this ques-
tion (i.e., endocrine therapy versus chemotherapy, each combined 
with dual HER2 blockade).
However, the majority of the ABC3 panelists (79.4%) and the 
German group of experts consider endocrine therapy as an option 
when the chemotherapy is finished. The endocrine treatment may 
serve as a maintenance treatment in the event of positive ER status, 
with the simultaneous continuation of the anti-HER2-targeted 
treatment, even if this has not yet been examined in the context of 
randomized clinical studies (LoE: 1C).
Progression under First-Line Therapy
The vast majority (90.6%) of the ABC3 panelists recommend 
the continuation of anti-HER2-targeted treatment in the event of 
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disease progression during or after first-line treatment, and for the 
following lines of therapy, in addition to any cytostatic or endo-
crine treatment (LoE: 1B). The German experts agree on this based 
on the principle that the treatment of patients with HER2-positive 
breast cancer should always include an anti-HER2 component.
Even if it is currently not clear for how long patients with meta-
static HER2-positive breast cancer require an anti-HER2-targeted 
treatment, further treatment with several lines of therapy is recom-
mended. The anti-HER2 treatment should also be continued in pa-
tients with long-term remissions, as long as the therapeutic index 
remains positive. More than 90% of the ABC3 panelists (92.8%) 
agree on this. Discontinuation of the anti-HER2 treatment after 
many years of a continuing and stable complete remission may be 
a useful option for some patients, if disease progression allows re-
starting the therapy at any time (LoE: expert opinion). The Ger-
man experts agree, and recommend in accordance with the current 
AGO recommendation [2], that the anti-HER2-targeted therapy 
must not be interrupted if the therapeutic index remains positive, 
because re-induction is not always successful.
There is unanimity among all ABC3 panelists (100%) and the 
German group of experts that patients who received an anti-HER2-
targeted treatment in the framework of a (neo)adjuvant treatment 
should not be excluded from clinical studies in the metastatic situ-
ation, because they continue to be candidates for anti-HER2-tar-
geted treatment.
Dual HER2 Blockade with Trastuzumab/Pertuzumab
For patients with HER2-positive metastatic disease, in the first-
line therapy, combinations of trastuzumab plus chemotherapy are 
superior to the combination of chemotherapy plus lapatinib, with 
respect to PFS and OS. This is valid independently of whether a 
patient was previously treated with trastuzumab in a (neo)adjuvant 
setting (disease-free interval (DFS) > 12 months) or not (LoE: 1A). 
Almost all ABC3 panelists (95.4%) agreed with this statement.
The German experts also agreed, in general. They added that, in 
Germany, dual HER2 blockade with trastuzumab/pertuzumab plus 
taxane is the standard first-line treatment for HER2-positive meta-
static breast cancer [2, 9]. The duration of DFS, defined as the in-
terval between the termination of (neo)adjuvant anti-HER2 ther-
apy and the appearance of metastases, does not play a role in the 
therapeutic decision (anti-HER2 treatment), in the opinion of the 
German experts.
The majority (85.7%) of the ABC3 panelists also consider the 
dual HER2 blockade with trastuzumab/pertuzumab plus taxane as 
the first-line standard, but only for patients not previously treated 
with anti-HER2-targeted therapy. In the first-line therapy of meta-
static patients with previous (neo)adjuvant anti-HER2 therapy, 
75.6% of all ABC3 panelists consider the dual HER2 blockade as an 
‘important option’. The ABC3 panelists refer to the CLEOPATRA 
study, in which the dual HER2 blockade plus docetaxel in the final 
evaluation [8] had demonstrated a significant and clear overall me-
dian survival benefit (p < 0.001) in comparison to trastuzumab/
docetaxel (LoE: 1A), taking into account that the majority of pa-
tients were not pretreated with HER2-targeted therapy. In addi-
tion, the relatively few anti-HER2-pretreated patients were disease 
free for more than 12 months (LoE: 1A) [9].
The German experts agree that the differentiation made by the 
ABC3 panelists mirrors exactly the published data, and therefore 
the weaker recommendation for anti-HER2-pretreated patients is 
understandable. Nevertheless, this vote cannot be adopted as such 
in Germany. According to the recommendation by the AGO [2], 
the dual HER2 blockade plus taxane is the first-line standard in 
both situations. The main justification thereof is the similar relative 
risk reduction attributable to the dual anti-HER2 blockade, irre-
spective of whether the patients were previously treated with (neo)
adjuvant trastuzumab or not.
In the event that chemotherapy with a taxane cannot be consid-
ered, from the German perspective, vinorelbine is an evidence-
based combination partner for trastuzumab/pertuzumab [10]. The 
German experts believe that, in spite of an insufficient amount of 
data, there is also an indication for the first-line dual HER2 block-
ade in the event of rapid progression with a (neo)adjuvant pre-
treatment within 12 months (DFS < 12 months). From the German 
perspective, treatment with trastuzumab emtansine (T-DM1) is an 
evidence-based alternative.
Pertuzumab in Later Therapy Lines?
The German group of experts agree with the majority of the 
ABC3 panelists (86.0%) that, in view of the lack of relevant data, 
there is currently no indication for further (beyond the first-line 
therapy) treatment of HER2-positive breast cancer patients with 
disease progression after first-line treatment with trastuzumab/
pertuzumab plus chemotherapy (no ‘pertuzumab beyond 
progression’).
However, later application of pertuzumab/trastuzumab plus 
chemotherapy – beyond the first-line therapy – can be an option if 
the patients did not receive dual HER2 blockade in the first-line 
therapy (LoE: 2C). This majority vote of the ABC3 panelists 
(75.6%) is supported by the German experts and would be espe-
cially beneficial for patients who could not receive pertuzumab as 
first-line therapy due to lack of approval.
Anti-HER2-Targeted Second-Line Treatment
Following a trastuzumab-based first-line therapy, further treat-
ment with T-DM1 as second-line treatment is currently the most 
efficient option. It is superior to the combination lapatinib/capecit-
abine as well as to other potential therapeutic options (‘treatment 
of physician’s choice’) and has a survival advantage [11, 12] (LoE: 
1A). Almost 90% of all ABC3 panelists (88.0%) agree with this 
statement, as does the German group of experts. The second-line 
treatment with T-DM1 is standard in Germany [2].
In the event of progression under trastuzumab-containing 
treatment, the majority of the ABC3 panelists (83.7%) believe that, 
for some patients, the combination trastuzumab/lapatinib (without 
chemotherapy) could also be a useful therapeutic option (LoE: 1B). 
However, to date, data is lacking on the use of this combination 
following progression under pertuzumab/trastuzumab and/or 
T-DM1. – From the German perspective, it should be noted that 
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the combination trastuzumab/lapatinib is approved only in steroid 
hormone receptor-negative, HER2-positive metastatic disease. 
Nevertheless, in the approval-relevant phase 3 study [13], this com-
bination attained a median survival advantage versus the mono-
therapy with lapatinib for the entire collective of patients, irrespec-
tive of the HR status.
Therapy Sequences and Combination Partners
In the absence of contraindications, all patients with HER2-pos-
itive metastatic breast cancer receive an anti-HER2-targeted treat-
ment in all treatment lines. However, the optimal therapeutic se-
quence of the currently available anti-HER2-targeted treatment 
options and the possible combination partners are unknown. They 
cannot be determined by vote, considering the increasing complex-
ity of the therapy regimen and multiple combination possibilities, 
including those in the various pretreatments. Therefore, the ABC3 
panel did not vote on the therapeutic sequences.
A clear majority (86.0%) of the ABC3 panelists, however, voted 
that docetaxel and paclitaxel are the preferable combination part-
ners for the dual HER2 blockade with trastuzumab/pertuzumab. 
Additional optional combination partners are vinorelbine (LoE: 
1B) and nab-paclitaxel (LoE: 2B). The German experts agree with 
this voting result.
For countries in which pertuzumab is not available, the majority 
of ABC3 panelists (87.8%) recommend that patients be treated in 
the first-line therapy with trastuzumab plus taxane or plus vinorel-
bin. The definitive therapeutic decision as to which kind of chemo-
therapy should be applied must be made individually, under con-
sideration of the usual criteria. The German experts agree with this.
The ABC3 panelists (90.6%) recommend the use of trastu-
zumab-based therapy for the later therapy lines of HER2-positive 
metastatic breast cancer. In addition to taxanes, possible combina-
tion partners are liposomal doxorubicin, eribulin mesylate, capecit-
abine, gemcitabine, or metronomic chemotherapy. The German 
experts agree in general, but point out that no data is currently 
available on the combination with gemcitabine or metronomic 
chemotherapy. From the German perspective, vinorelbine is an ad-
ditional combination partner.
HER2-Negative Metastatic Breast Cancer
ER+/HER2– Metastatic Breast Cancer
Over 90% of the ABC3 panelists (92.6%) and the German group 
of experts agreed that patients with HER2-negative (HER2–) meta-
static breast cancer and positive estrogen receptor status (ER+) 
should preferably receive endocrine therapy and that this is basi-
cally also true for patients with visceral metastases. Exceptions are 
proven endocrine resistance or the occurrence of a potentially life-
threatening situation (‘visceral crisis’).
Postmenopausal Patients
For the endocrine first-line treatment of postmenopausal pa-
tients, the ABC3 panelists (84.0%) recommend an aromatase in-
hibitor, tamoxifen, or fulvestrant. The definitive therapeutic deci-
sion should be made depending on the adjuvant endocrine pre-
treatment (type and duration) and the disease-free period after 
termination of the adjuvant treatment (LoE: 1A). The German ex-
perts agree with this, but add that the first-line therapy should 
preferably include an aromatase inhibitor or fulvestrant (500 mg).
Endocrine combination therapy does not play an important role 
in Germany. Therefore, the German experts agree with the slight 
absolute majority vote (53.4%) of the ABC3 panelists who advo-
cated not to use combined endocrine first-line treatment with a 
non-steroidal aromatase inhibitor plus fulvestrant in postmeno-
pausal patients without prior adjuvant endocrine treatment. This 
vote was made against the background of differing results of 2 ran-
domized phase 3 studies [14, 15] on ER+/HER2– postmenopausal 
patients with metastatic breast cancer.
In the Southwest Oncology Group (SWOG) study [14], the 
first-line treatment consisting of non-steroidal aromatase inhibi-
tors plus fulvestrant had a significant advantage in terms of PFS 
and OS compared with the aromatase inhibitor-only treatment. In 
the FACT study [15] with a very similar design, no advantage 
could be shown. A subgroup analysis demonstrated that, in the 
SWOG study, the advantage could be demonstrated only in pa-
tients with no adjuvant endocrine (tamoxifen) pretreatment and 
with a very long DFS (≥ 10 years).
The German experts point out that, in Germany, most patients 
with ER+/HER2– breast cancer receive adjuvant endocrine pre-
treatment, so that this question is irrelevant in day-to-day clinical 
practice. The negative vote is explained by the German experts by 
the fact that, in the design of the SWOG study [14], a control arm 
with fulvestrant (500 mg) as monotherapy was missing, which was 
also pointed out by the SWOG study authors themselves. Thus, it is 
difficult to estimate the position of the combination (of non-steroi-
dal aromatase inhibitors/fulvestrant 250). It must also be taken 
into account that the benefit of the aromatase inhibitors/fulves-
trant combination in this subgroup of patients pretreated with ta-
moxifen was only small.
For postmenopausal patients with ER+/HER2– metastatic 
breast cancer who experience disease progression under a non-ste-
roidal aromatase inhibitor, an option exists of further treatment 
with an aromatase inhibitor in combination with the mammalian 
target of rapamycin (mTOR) inhibitor everolimus. This therapy 
approach enables significant PFS extension (p < 0.001) and a nu-
merical median survival advantage of almost 5 months [16]. The 
German experts agree with this majority vote (84.6%) of the ABC3 
panelists. There is agreement that the therapeutic decision must be 
made individually, considering the increased toxicity induced by 
everolimus (LoE: 1B). There is currently no predictive biomarker 
for identifying patients who will benefit from the addition of an 
mTOR inhibitor.
In addition, the German experts add that the combination of 
exemestane/everolimus and fulvestrant (500 mg) constitute valid 
first-line options for postmenopausal patients with adjuvant endo-
crine pretreatment. The indication for this combination should be 
based mainly on the disease dynamics, taking into account the ex-
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pected side effects and the wishes of the informed patient. From 
the German perspective, the patient’s age as such does not play a 
role in the therapeutic decision; the data of the non-interventional 
BRAWO study did not show any association between age and side 
effects [17].
Significance of Palbociclib
A potential new therapeutic option for the first-line treatment 
of ER+/HER2– postmenopausal patients with metastatic breast 
cancer is the cyclin-dependent kinase (CDK)4/6 inhibitor palboci-
clib, which demonstrated an impressive PFS advantage in combi-
nation with the aromatase inhibitor letrozole in a randomized 
phase 2 study versus the aromatase inhibitor alone (HR 0.488; p = 
0.0004) [18]. Just over half (51.1%) of all ABC3 panelists voted that 
the phase 2 data must still be confirmed by a phase 3 study [19] 
before the combination of palbociclib/aromatase inhibitor can be 
classified as recommended therapy option. Almost 40% of the 
ABC3 panelists (39.5%) voted against this and were of the opinion 
that the phase 2 data already justify clinical use.
However, beyond the first-line treatment, a clear majority of 
85.7% of the ABC3 panelists consider the combination of palboci-
clib/fulvestrant as an option for pre-, peri-, and postmenopausal 
patients with ER+/HER2– metastatic breast cancer. The panelists 
point out the significant PFS advantage shown in the interim anal-
ysis of the PALOMA-3 study with the approximate median value 
of 5 months (HR 0.422; p < 0.000001) and improved quality of life 
[20]. Pre- and perimenopausal patients additionally need a lutein-
izing hormone-releasing hormone (LHRH) agonist (LoE: 1B). 
Again, for palbociclib, there is no predictive biomarker.
The German experts point out that palbociclib has not yet been 
approved in Germany. The drug is registered in the USA, and Ger-
man and/or European approval is expected in the course of 2016. 
In addition, phase 3 data is still missing for the palbociclib/aro-
matase inhibitor combination. In Germany a phase 3/4 intergroup 
study on the use of palbociclib is currently in preparation.
Endocrine Treatment Sequences
The optimal endocrine therapy sequence following an endocrine 
first-line treatment cannot be defined as it depends on each previ-
ously administered treatment. More than 90% of the ABC3 panelists 
(92.5%) consider the administration of aromatase inhibitors, tamox-
ifen, fulvestrant/palbociclib, aromatase inhibitors/everolimus, ta-
moxifen/everolimus, fulvestrant alone, and megestrole acetate and 
estradiole as possible therapeutic options (LoE: 1A). Due to insuffi-
cient study data either comparing combination therapies consisting 
of an endocrine plus a biological substance or in comparison with 
monochemotherapy (e.g. capecitabine), no further evaluation is pos-
sible. We must wait for the results of the ongoing studies.
The German experts agree in general, but point out the still 
pending approval of palbociclib and add that, in Germany, gesta-
gens and estradiol are currently used only in individual cases and 
that in case of fulvestrant the approved 500-mg dose must be used. 
From the German prospective, a well-tolerated chemotherapy can 
also be considered as an alternative to endocrine third-line therapy.
Premenopausal Patients
Almost all ABC3 panelists (93.0%) voted for the statement that, 
for premenopausal patients with ER+/HER2– metastatic breast 
cancer who should receive endocrine therapy, ovarian suppression 
or ablation combined with an additional endocrine substance is the 
preferred therapeutic option (LoE: 1B). The ovarian ablation via 
laparoscopic bilateral oophorectomy guarantees adequate estrogen 
suppression including contraception, prevents potential initial 
flare phenomena which can occur under LHRH agonists and pos-
sibly also increases the possibility of participating in clinical studies 
(LoE: expert opinion). In addition, 90.6% of all ABC3 panelists be-
lieve that ovarian irradiation is also a possibility to achieve perma-
nent ovarian ablation.
The German group of experts agrees with these votes. They 
point out that, in premenopausal patients, the additional ovarian 
suppression is – due to published data – a standard measure ac-
companying any endocrine treatment [21]. Ovarian suppression 
can be achieved either pharmacologically by gonadotropin-releas-
ing hormone (GnRH) analogues or surgically by bilateral oopho-
rectomy. Radiation therapy should only be used if contraindica-
tions against both these options are present (such as coagulation 
disorders or other conditions that do not allow surgery). One 
should be aware that, in case of irradiation, complete endocrine ab-
lation is only achieved with a substantial delay.
The ABC3 panelists (95.2%) voted for the use of either an aro-
matase inhibitor or tamoxifen as an additional endocrine therapy 
for premenopausal patients, depending on the kind and duration 
of the adjuvant endocrine pretreatment. For pharmacological rea-
sons, an aromatase inhibitor absolutely requires additional ovarian 
suppression or ablation (LoE: 1B). This is currently also valid for 
fulvestrant, which in the opinion of the panelists can also be con-
sidered an option (LoE: 1C). The German experts agree with this.
Triple-Negative Advanced Breast Cancer
The ABC3 panelists (97.7%) and the group of German experts 
agree that, if other data is missing, the same chemotherapy recom-
mendations are valid for patients with advanced, non-BRCA-mu-
tated, triple-negative breast cancer (TNBC) as for patients with 
HER2-negative disease (LoE: 1A). Irrespective of the BRCA status, 
a clear majority of the ABC3 panelists (90.6%) evaluated carbopl-
atin treatment as an important therapeutic option for TNBC pa-
tients pretreated with anthracyclines and taxanes in the (neo)adju-
vant setting. Carboplatin has a comparable efficacy to docetaxel 
but with a more favorable side effect profile (LoE: 1A). The Ger-
man experts also agree with this.
Additional Statements
Metronomic Chemotherapy
The German experts agree with the majority of the ABC3 pan-
elists (88.3%) that metronomic chemotherapy may constitute a 
reasonable therapy for patients without increased remission pres-
sure who do not require rapid tumor regression (LoE: 1B). The 
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combination of low-dose cyclophosphamide and methotrexate 
(CM) is a well-investigated regimen [22]. Other regimens currently 
evaluated for their metronomic therapeutic concepts are, e.g., those 
with capecitabine and oral vinorelbine. However, results of rand-
omized studies comparing metronomic chemotherapy concepts 
with conventional dose regimens are still lacking. The ABC3 pan-
elists and the German experts agree that such studies are 
necessary.
Re-Induction of Anthracyclines
Re-induction of anthracyclines in the metastatic situation is an 
evidence-based option for HER2-negative breast cancer patients 
who were previously treated with anthracyclines as adjuvant. Al-
most all ABC3 (93.1%) panelists supported this statement. Prereq-
uisites are that the cumulative total dose of anthracyclines has not 
yet been reached and that there are no cardiac contraindications. 
Ideally, the patient should be disease free for at least 1 year after the 
adjuvant treatment. The German experts agree with this majority 
vote of the panelists and added that, for the rechallenge, anthracy-
cline schemes with good cardiac tolerability would be particularly 
suitable, such as weekly anthracycline administration or pegylated 
liposomal formulations. Such a regimen can be an option even if 
the cumulative total dose has been reached.
BRCA-Mutated Metastatic Breast Cancer
The German experts agree with the majority vote of the ABC3 
panelists (86.3%), namely that platinum-based regimens are a pref-
erable therapeutic option for metastatic patients with BRCA-mu-
tated TNBC or endocrine-resistant breast cancer, if these women 
were already previously treated with anthracyclines or taxanes in 
the adjuvant or the metastatic situation. Additional conditions are 
that the patients have not yet received any platinum and that they 
cannot be included in a relevant controlled clinical study (LoE: 
1A). – The ABC3 panelists (90.6%) and the German experts point 
out that BRCA germline testing should be performed in TNBC pa-
tients with negative family history, if any clinical consequences 
could result from this.
Bone Metastases
Also concerning the application of anti-resorption substances 
(‘bone-modifying agents’) such as bisphosphonates and deno-
sumab, there is agreement between the German experts and the 
majority of the ABC3 panelists (95.4%): There is an indication for 
their use as a routine addition to further oncological treatment in 
patients with bone metastases (LoE: 1A). According to an ABC3 
vote, the application of zoledronic acid every 3 months is not infe-
rior to the standard monthly dosing (LoE: 1B). The German ex-
perts restrict this statement and maintain that a once-in-3-months 
dose can only be considered after a stable situation has been 
reached under the monthly standard dose. If there are no contrain-
dications, an additional supplementation with calcium and vitamin 
D should definitely be recommended, and supplementation with 
denosumab is obligatory (LoE: 1C).
Brain Metastases in HER2-Positive Disease
More than 90% of the ABC3 panelists (95.2%) voted for the un-
changed continuation of systemic treatment in patients with 
HER2-positive breast cancer with brain metastases, as long as the 
extracranial disease is stable (LoE: 1C). For patients in whom the 
brain metastases are the only clinical localization of metastases, it is 
unclear – according to the vote of the ABC3 panelists (83.3%) – 
whether chemotherapy in addition to the local measures can sub-
stantially improve the course of the disease. However, it is recom-
mended to restart an anti-HER2-targeted therapy (trastuzumab) if 
this was stopped in the meantime (LoE: 1C). The German experts 
agree with this.
‘Next-Generation Sequencing’
The ABC3 panelists (94.4%) and the German experts agree that 
data obtained from genomic testing by ‘next-generation sequenc-
ing’ (NGS) in order to detect potential molecular alterations re-
garding therapy and course of disease in patients with advanced 
breast cancer has not yet been adequately validated to allow clinical 
decisions to be based thereon. Results from clinical studies docu-
menting an advantage of therapeutic decisions based on NGS are 




A majority of 77.7% of all ABC3 panelists define an oligometa-
static breast cancer as a disease with low metastatic tumor burden 
and limited number of metastatic lesions. The latter means, accord-
ing to the ABC3 vote, that a maximum of 5 lesions are present, 
which do not necessarily have to be in the same body organ. The 
German experts do not agree with this last definition: From the Ger-
man perspective, oligometastatic disease is defined as a limited num-
ber of metastases in one body organ. There is unanimity that local 
measures are an important potential therapy option in oligometa-
static disease; the aim of the therapy is complete clinical remission.
‘Multiple Chronic Conditions’
All ABC3 panelists (100%) define patients with ‘multiple chronic 
conditions’ (MCCs) as patients who have multiple (clinically rele-
vant) comorbidities, e.g. cardiac diseases, reduced renal and/or he-
patic function, or an autoimmune disease. MCC patients require 
close monitoring and special individual therapy concepts. It is diffi-
cult to define general therapy recommendations for the manage-
ment of these patients (‘difficult to account for all of the possible ex-
trapolations to develop specific recommendations for care’).
Supportive and Palliative Treatment
The question of supportive therapy and palliative treatment of 
patients with advanced breast cancer was not publicly voted on at 
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the ABC3 meeting so that no comment was made from the Ger-
man perspective.
ABC3 – A Forum for Patient Advocates
During the ABC3 conference, the representatives of interna-
tional patient support groups also held discussions. Overall, 66 rep-
resentatives from Europe, Asia, the Middle East, Africa, Australia, 
North, South and Central America were present. They presented 
the results of their work in the plenary session of the ABC3 confer-
ence on November 7, 2015. In a moving speech by Shirley A. 
Mertz, a patient advocate from the USA, the support groups ex-
pressed their gratitude to the physicians for their on-duty commit-
ment to patients and emphasized how important this commitment 
is for each individual patient. Mertz: ‘Your work affects how long 
we live and the quality of life we have!’
The advocacy groups also expressed their gratitude for the pos-
sibility to take part in the ABC conference and for the opportunity 
of international exchange between themselves and the physicians. 
This is particularly important considering the complexity of the 
disease. The support groups invited the scientists, caregivers, the 
industry, the worldwide advocacy groups, and the representatives 
of the media to establish a cooperation aimed at further improving 
the prognosis of patients with metastatic breast cancer.
Four key goals were defined for the near future:
• Creation of an ‘ABC Global Advocate Community’. Its goal 
would be the development of a common network to exchange ex-
periences and to promptly discuss and implement common goals 
and strategies.
• In close relationship with this, initiation of an ‘Alliance’ of 
regular dialog between the support groups, for example by the use 
of webinars. The focus of this ‘Alliance’ should be therapeutic rec-
ommendations and aspects of quality of life.
• The educational work with metastatic breast cancer patients 
regarding the disease itself but also the therapeutic options and 
support group possibilities should be further coordinated and im-
proved. This also includes translating the ABC3 consensus into the 
languages spoken in the individual countries.
• In the future, the representatives of the advocacy groups also 
want to meet each year in person, in order to establish an open 
path of discussion and exchange of opinions for advancing the re-
quired goals.
Conclusions and Prospects
The ABC consensus again provided a forum for an informative 
discussion on the most recent developments related to advanced 
breast cancer. The ABC meeting is, in this respect, the consequent 
addition to the St. Gallen consensus conference on early breast 
cancer. The next ABC4 consensus conference will be held on No-
vember 9–11, 2017. The next AGO ‘State-of-the-Art Meeting’, dur-
ing which the annually updated AGO-Mamma guidelines for the 
diagnosis and therapy of breast cancer will be presented, will be 
held on March 5, 2016.
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